Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

Blood

Volumn 124, Issue 25, 2014, Pages 3829-3830

  McMullen, Julie R ^a   Boey, Esther J H ^a   Ooi, Jenny Y Y ^a   Seymour, John F ^b,c   Keating, Michael J ^d   Tam, Constantine S ^b,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRUTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

BONE MARROW SUPPRESSION; CARDIOVASCULAR RISK; CHRONIC LYMPHATIC LEUKEMIA; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART PROTECTION; HUMAN; INFECTION; LETTER; LEUKEMIA RELAPSE; MANTLE CELL LYMPHOMA; NONHUMAN; PATIENT CARE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINUS RHYTHM; TAKOTSUBO CARDIOMYOPATHY; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; METABOLISM; NEWBORN; RAT; RISK FACTOR;

ANIMALS; ANIMALS, NEWBORN; ATRIAL FIBRILLATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; MYOCYTES, CARDIAC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRIMIDINES; RATS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84919477868     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-604272     Document Type: Letter

References (10)

1. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15(10):1090-1099.
2. Byrd JC, Brown JR, O'Brien S, et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
3. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
4. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
5. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48-58.
6. Treon SP, Palomba L, Tripsas C, et al. Ibrutinib in previously treated patients with Waldenstrom's macroglobulinemia [abstract]. In: Proceedings of the 8th International Workshop on Waldenstrom's Macroglobulinemia; August 13-17, 2014; London, United Kingdom. Abstract X.5.
7. Barth AS, Merk S, Arnoldi E, et al. Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular-like genomic signature. Circ Res. 2005;96(9):1022-1029.
8. McMullen JR, Amirahmadi F, Woodcock EA, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA. 2007;104(2):612-617.
9. Pretorius L, Du XJ, Woodcock EA, et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol. 2009;175(3):998-1009.
10. Weeks KL, Gao X, Du XJ, et al. Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail. 2012;5(4):523-534.